Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient

Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e. induction chemotherapy followed by surgery, is standard of care in highly selected patients with localized disease. Platinum-doublet chemotherapy is th...

Full description

Bibliographic Details
Main Authors:	M. Criel, A. Vandermeulen, K. Vanhove, C. Van De Kerkhove, K. Nackaerts, M. Lambrecht, P. Berkovic
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Current Problems in Cancer: Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621920300351

id	doaj-b95aa7f7d04c4678bb45965359b7b985
record_format	Article
spelling	doaj-b95aa7f7d04c4678bb45965359b7b9852021-09-03T04:48:08ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192020-12-012100035Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patientM. Criel0A. Vandermeulen1K. Vanhove2C. Van De Kerkhove3K. Nackaerts4M. Lambrecht5P. Berkovic6Department of Respiratory Oncology, University Hospitals Leuven, Belgium; Department of Respiratory Oncology, Ziekenhuis Oost-Limburg Genk, Belgium; Corresponding author.Department of Radiation Oncology, University Hospitals Leuven, BelgiumDepartment of Respiratory Oncology, University Hospitals Leuven, BelgiumDepartment of Respiratory Oncology, University Hospitals Leuven, BelgiumDepartment of Respiratory Oncology, University Hospitals Leuven, BelgiumDepartment of Radiation Oncology, University Hospitals Leuven, BelgiumDepartment of Radiation Oncology, University Hospitals Leuven, BelgiumMalignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e. induction chemotherapy followed by surgery, is standard of care in highly selected patients with localized disease. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. Currently, there are no good recommendations for second-line treatment due to the lack of a clear survival benefit. We report the case of an MPM patient that showed a remarkable response through the combination of immunotherapy and radiotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of immunotherapy and radiotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.http://www.sciencedirect.com/science/article/pii/S2666621920300351
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	M. Criel A. Vandermeulen K. Vanhove C. Van De Kerkhove K. Nackaerts M. Lambrecht P. Berkovic
spellingShingle	M. Criel A. Vandermeulen K. Vanhove C. Van De Kerkhove K. Nackaerts M. Lambrecht P. Berkovic Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient Current Problems in Cancer: Case Reports
author_facet	M. Criel A. Vandermeulen K. Vanhove C. Van De Kerkhove K. Nackaerts M. Lambrecht P. Berkovic
author_sort	M. Criel
title	Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
title_short	Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
title_full	Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
title_fullStr	Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
title_full_unstemmed	Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
title_sort	robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient
publisher	Elsevier
series	Current Problems in Cancer: Case Reports
issn	2666-6219
publishDate	2020-12-01
description	Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e. induction chemotherapy followed by surgery, is standard of care in highly selected patients with localized disease. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. Currently, there are no good recommendations for second-line treatment due to the lack of a clear survival benefit. We report the case of an MPM patient that showed a remarkable response through the combination of immunotherapy and radiotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of immunotherapy and radiotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.
url	http://www.sciencedirect.com/science/article/pii/S2666621920300351
work_keys_str_mv	AT mcriel robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT avandermeulen robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT kvanhove robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT cvandekerkhove robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT knackaerts robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT mlambrecht robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient AT pberkovic robustdiseasecontrolfollowingsequentialimmunotherapyandradiotherapyinamalignantpleuralmesotheliomapatient
_version_	1717817880232329216

Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient

Similar Items